At the heart of this research is tegoprazan, a potassium-competitive acid blocker (P-CAB) that has shown promise in managing conditions like gastroesophageal reflux disease and peptic ulcers. Unlike conventional proton pump inhibitors, tegoprazan acts by blocking the potassium-binding site of the gastric proton pump, leading to a quicker onset of acid suppression. The formulation of this drug into an effective tablet form, however, poses considerable challenges due to its crystalline nature, which may affect its absorption.

The rationale behind this study lies in the struggle faced by formulators when it comes to poorly soluble drugs. Many promising drug candidates fail during the development process primarily due to inadequate solubility, which hampers their bioavailability once administered. The research team tackled this issue head-on by employing a long-term crystallization-suppressing solid dispersion technique, which is a sophisticated method designed to enhance the solubility and stability of active pharmaceutical ingredients.

The long-term crystallization-suppressing solid dispersion technology developed by Kang and colleagues relies on creating a composite material where the drug particles are embedded within a polymer matrix. This configuration helps to stabilize the drug in its amorphous state, which is crucial for achieving improved solubility. By inhibiting crystallization, the researchers have paved the way for a more effective formulation that can rapidly dissolve and be absorbed by the body, ultimately leading to enhanced therapeutic outcomes.

In this study, the researchers meticulously prepared the tegoprazan tablets, tuning various parameters such as the types of polymers used and the composition ratios. Through a series of experimental trials, they evaluated the physical and chemical stability of the tablets over extended periods. This assessment was critical, as it provided insights into the long-term efficacy of the formulation in real-world conditions, where factors like humidity and temperature could potentially impact performance.

Moreover, the evaluation process included rigorous testing to assess the release characteristics of the tegoprazan tablets. The research team employed sophisticated methodologies, including in vitro dissolution studies that simulate gastrointestinal conditions. By analyzing how quickly and efficiently the drug released from the solid dispersion, the researchers were able to collect valuable data that would determine the practical usability of the tablets in clinical settings.

As a result of their innovative approach, the researchers successfully demonstrated that the solid dispersion formulation not only prevented crystallization but also significantly enhanced the dissolution rates compared to those of conventional formulations. This finding is pivotal, as it demonstrates the potential of this technology to improve the formulation of not just tegoprazan, but numerous other poorly soluble drugs currently in development.

The implications of this research extend beyond the laboratory. Enhanced solubility and stability can lead to better patient compliance with drug regimens, as individuals are more likely to adhere to treatments that yield prompt relief from symptoms. Additionally, the pharmaceutical industry stands to benefit significantly from this advancement, as companies could potentially bring more effective therapies to market, addressing unmet medical needs.

In conclusion, the work conducted by Kang, Won, and Yang represents a crucial step forward in the quest for more efficient drug formulations. Their exploration into long-term crystallization-suppressing solid dispersion technology has opened up new pathways for developing effective treatments for patients suffering from gastric acid-related disorders. By overcoming the barriers associated with poor solubility, this team has set a notable precedent that inspires further research and innovation within the pharmaceutical field.

This study not only contributes to the body of knowledge surrounding drug formulation techniques but also emphasizes the ongoing need for research in this vital area of health science. As the pharmaceutical landscape continues to evolve, the insights gained from this research will undoubtedly influence future studies and the strategies used to combat the challenges presented by solid drug formulations.

The advancement of tegoprazan tablet formulation stands as a testament to the power of collaboration and interdisciplinary approaches in science. This research exemplifies how targeted technology can be leveraged to solve complex problems and ultimately improve patient care. As we anticipate the publication of this study in Journal of Pharmaceutical Investigation in 2026, the excitement within the pharmaceutical community grows, eager to see how these findings will translate into clinical practice and therapeutics.

In a world where access to effective medications is crucial, studies like this one present not just scientific progress but hope. With continued innovation, the future of pharmaceuticals looks promising, guiding the industry toward more effective solutions for patients globally.

Subject of Research: Preparation and evaluation of tegoprazan tablets using long-term crystallization-suppressing solid dispersion technology.

Article Title: Preparation and evaluation of tegoprazan tablets using long-term crystallization-suppressing solid dispersion technology.

Article References: Kang, S., Won, YH., Yang, JH. et al. Preparation and evaluation of tegoprazan tablets using long-term crystallization-suppressing solid dispersion technology. J. Pharm. Investig. (2026). https://doi.org/10.1007/s40005-025-00798-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s40005-025-00798-8

Keywords: tegoprazan, solid dispersion technology, drug formulation, gastric acid-related disorders, pharmaceutical innovation.

For decades, the greatest challenge in oncology has been the difficulty of studying cancer’s inception. Traditionally, the healthcare community only encounters tumors once they have visibly manifested with symptoms, leaving a vast knowledge gap about the subtle and complex changes that occur before malignancy takes root. Conventional laboratory models—often dependent on animal systems—fail to adequately mimic the highly specialized human tumor microenvironment. These limitations have historically handicapped drug development, biomarker discovery, and preventative strategies.

Enter the realm of 3D bioprinting and microfluidic organ-on-a-chip platforms, powerful bioengineering tools that offer exquisite control over cellular architecture, extracellular matrix composition, and biochemical gradients. Led by Dr. Luiz Bertassoni, whose previous work revolutionized vascular 3D printing, scientists have now created sophisticated chip-based systems that authentically reproduce the interplay between human bone tissue and tumors. Such biomimetic platforms rewrite the rules by bridging existing gaps between in vivo complexity and traditional in vitro simplicity.

At the heart of this innovation lies the capacity to recapitulate early tumorigenesis inside a laboratory setting. By bioprinting living human cells in three-dimensional configurations, researchers generate tissue constructs that mirror physiological conditions far more accurately than flat monolayer cultures. These models permit controlled manipulation of genetic mutations, cellular heterogeneity, and environmental stresses—conditions under which precancerous lesions can be observed to either regress or progress toward full malignancy. This capability affords an unprecedented opportunity to decode the variable trajectories of early cancer development.

Furthermore, this biofabrication approach dovetails with the Food and Drug Administration’s growing emphasis on reducing animal testing by adopting human-relevant experimental models. Engineered tissues pave the way for New Approach Methodologies that enhance translational validity and ethical standards while facilitating high-throughput drug screening. These developments align with regulatory evolution, promising to fast-track safer, more effective cancer therapeutics and diagnostic tools.

The integration of disciplines is a defining feature advancing this frontier. Oncology, materials science, computational modeling, and microengineering unite to tackle complex biological questions. Individually, these fields wield specialized expertise, but combined, they construct a robust platform capable of simulating real-time tumor microenvironments. Such cross-pollination reveals biological dynamics otherwise inaccessible, such as early molecular signaling cascades and stromal-immune cell interactions instrumental in cancer establishment.

Haylie Helms, a biomedical engineer and environment architect of early cancer models, emphasizes the profound potential of this work. Her doctoral research harnesses single-cell resolution 3D bioprinting to fabricate microtumors that replicate patient-specific cancer pathophysiology. These tailor-made systems extend beyond basic research, illuminating pathways toward personalized medicine where treatment regimens are precisely tailored according to an individual’s tumor imprint and therapeutic response.

Experimental frameworks designed within these biofabricated tissues also serve as crucial testbeds for biomarker identification. Detecting cancer earlier demands sensitive, reliable biological red flags—molecular signatures—observable before clinical symptoms manifest. Engineered models thus propel the discovery pipeline, enabling systematic evaluation of candidate biomarkers under controlled but physiologically relevant conditions.

An exciting implication of this technology is the advent of “cancer interception,” a preventive approach aiming to intercept malignancy prior to tumor mass formation. Unlike conventional therapies that mainly address advanced disease stages, interception relies on mechanistic understanding derived from early-stage models. Intervention at these junctures promises a paradigm shift in reducing cancer morbidity and mortality by circumventing progression rather than solely treating established tumors.

The scientific community acknowledges that these advances arise at a confluence of opportunity—where engineering precision meets biological complexity. As Bertassoni notes, “We are at a watershed moment where cancer biology, cutting-edge fabrication, and clinical application are synchronizing like never before.” Harnessing these technologies to systematically map cancer’s earliest events could profoundly alter the landscape of oncology.

Despite its promise, this biofabrication approach is in nascent stages, requiring continued interdisciplinary collaboration and refinement. Standardizing protocols, enhancing the fidelity of biochemical and mechanical cues, and scaling production for widespread use remain crucial challenges. Nonetheless, the trajectory is unmistakable: the future of cancer research is increasingly bioengineered, drawing ever closer to replicating the intricacies of human disease.

As these engineered systems mature, they not only yield platforms for understanding cancer but also represent critical tools for precision treatment and drug development. Patients could benefit from treatments formulated and validated using models derived directly from their tumor biopsy cells. The enhanced predictive validity of such models holds the key to reducing trial-and-error medicine, sparing patients unnecessary toxicity while improving therapeutic outcomes.

In sum, the intersection of engineering and biomedical sciences is forging new horizons in early cancer detection and prevention. Through the lens of 3D bioprinting and organ-on-chip methodologies, researchers are unraveling the enigma of cancer’s beginnings. This revolution promises to empower clinicians with knowledge and tools that will shift oncology’s focus upstream—catching cancer before it unleashes its devastating impact.

Subject of Research: Engineering and biofabrication of early cancer models

Article Title: Engineering and biofabrication of early cancer models

News Publication Date: 3-Nov-2025

Web References:
DOI link to article

Image Credits: OHSU/Christine Torres Hicks

Keywords: Organoids, Tissue engineering

The MYC protein, long recognized as a central oncogenic driver implicated in up to 70% of human cancers, has historically been labeled “undruggable” due to its lack of conventional binding pockets suitable for small molecule inhibitors. MYC functions primarily by regulating gene transcription and cellular proliferation, but its oncogenic activity stems from complex protein–protein interactions that have resisted traditional pharmacological intervention. Recent insights revealed that the interaction between MYC and WDR5 is indispensable for the maintenance of MYC’s oncogenic functions, thereby spotlighting WDR5 as a novel and promising target in therapeutic development.

Breaking new ground, the research team employed Insilico’s generative AI-driven platform, Chemistry42, creating novel small molecules that precisely engage the WDR5 interface critical for MYC binding. The platform enabled a ligand-centric and scaffold-hopping strategy enhanced by ’anchor points,’ which preserved pharmacophoric features essential for high-affinity binding. Among the AI-generated candidates, two compounds distinguished themselves: compound 8 exhibited inhibitory potency with an IC50 value of 16.35 micromolar, while compound 9 demonstrated a significantly improved IC50 of 1.91 micromolar. These findings indicated marked improvements over a reference molecule, which displayed an IC50 of 20.86 micromolar, signaling notable enhancement in targeting this challenging PPI landscape.

Recognizing the potential of these initial hits, further optimization was carried out through rigorous physics-based modeling facilitated by Chemistry42’s AlChemistry module. This approach enabled deep structural analysis and refinement of molecular interactions and binding conformations within the WDR5-MYC interface. As a result, lead compounds with sub-micromolar affinities were engineered, culminating in the identification of the standout molecule 9c-1. This lead showed a remarkable 35-fold increase in inhibitory activity relative to earlier analogs, specifically compound 3, showcasing exceptional binding strength and specificity against WDR5. Such potency positions 9c-1 as a trailblazer in the design of efficacious inhibitors capable of disrupting MYC-driven oncogenesis through direct interference with its protein–protein engagement.

The implications of this breakthrough are profound. The successful application of an AI-guided generative chemistry technique, integrated seamlessly with physics-anchored validation, underscores a paradigm shift in tackling traditionally “undruggable” targets. This study exemplifies how advanced computational platforms can rapidly generate candidate molecules with therapeutic promise, accelerating early-stage drug discovery timelines dramatically compared to conventional methodologies. Insilico Medicine’s innovative combination of machine learning and molecular modeling successfully circumvents longstanding challenges in drug design, especially for complex PPIs long deemed refractory to small molecule intervention.

Dr. Xiao Ding, Senior Vice President and Head of Chemistry & DMPK at Insilico Medicine, emphasized the significance of these findings, stating, “Our AI-powered platforms are transforming drug discovery by unlocking possibilities for targets previously considered inaccessible. This project demonstrates the synergistic power of generative chemistry aligned with physics-based modeling, delivering molecules that could herald new therapeutic paradigms for cancers driven by MYC.” The integration of computational creativity with empirical rigor has expedited the transition from conceptual targets to potent leads, offering hope for treating malignancies with profound unmet medical needs worldwide.

This achievement builds on a rich legacy of Insilico Medicine’s leadership in artificial intelligence applications for drug design. Initially conceptualized in 2016 within peer-reviewed literature as a pioneering use of generative AI for molecule creation, Insilico’s platforms have evolved to commercial maturity via Pharma.AI, a comprehensive digital ecosystem deployed extensively in early drug development pipelines. By uniting deep generative neural networks, reinforcement learning techniques, transformer architectures, and physics-based simulations, Insilico Medicine has optimized target identification and compound generation, significantly compressing drug discovery phases from an average 2.5–4 years down to 12–18 months per program.

Moreover, leveraging automated synthesis and high-throughput biological testing, Insilico Medicine has propelled over two dozen internal programs between 2021 and 2024, synthesizing and validating 60–200 molecules per candidate initiative. This integrated AI-drug discovery approach not only expedites lead identification but enhances molecular novelty and diversity—overcoming traditional attrition hurdles frequently encountered in medicinal chemistry campaigns focused on complex targets such as transcription factor PPIs.

The WDR5-MYC inhibitory compounds represent a new class of focused PPI disruptors, embodying a strategic shift to modulate oncogenic pathways at the protein interaction level rather than canonical enzymatic inhibition. Disrupting the assembly of oncogenic transcriptional complexes via WDR5 offers a promising intervention point with the potential to arrest cancer proliferation and survival mechanisms. Crucially, this approach illustrates the feasibility of rational PPI drug design supported by AI, challenging preconceived limitations in medicinal chemistry and expanding the therapeutic landscape for challenging targets across oncology and beyond.

Looking forward, the medicinal chemistry team aims to advance the 9c-1 lead through preclinical evaluations, exploring pharmacokinetics, toxicity profiles, and efficacy in cancer models. The translational potential of these findings opens avenues for addressing cancers driven by MYC dysregulation, including lymphoma, leukemia, and a spectrum of solid tumors. Furthermore, the AI-driven discovery methodology exemplified here serves as a model for future drug discovery efforts targeting other difficult proteins implicated in disease pathogenesis.

In conclusion, the collaboration between Insilico Medicine and Huadong Medicine Company showcases the transformative impact of integrating generative AI and physics-based modeling in uncovering novel therapeutic agents. This research not only delivers powerful WDR5 inhibitors with the potential to modulate the MYC oncogenic axis—a longstanding unmet challenge in oncology—but also validates an innovative drug discovery paradigm poised to revolutionize how next-generation medicines are designed and optimized.

Subject of Research: Discovery of small-molecule inhibitors targeting the WDR5-MYC protein–protein interaction using AI-driven generative chemistry and physics-based molecular modeling.

Article Title: (Not explicitly provided; refer to DOI link)

News Publication Date: May 28

Web References:

• Chemical Biology & Drug Design article: https://onlinelibrary.wiley.com/doi/10.1111/cbdd.70129
• Insilico Medicine website: https://insilico.com/
• Pharma.AI platform: https://pharma.ai/
• Previous Insilico concept article: https://pmc.ncbi.nlm.nih.gov/articles/PMC5355231/

References: DOI 10.1111/cbdd.70129 (journal article detailing the research)

Keywords

Medicinal chemistry, drug discovery, generative artificial intelligence, protein–protein interaction inhibitors, WDR5, MYC oncogene, pharmacophore modeling, molecular docking, physics-based molecular modeling, AI-driven chemistry, cancer therapeutics, small-molecule inhibitors

Recent breakthrough research from an esteemed consortium, including the University of Portsmouth, the University of Southampton, King’s College London, and the Massachusetts Institute of Technology, has published new guidelines to address this challenge. These guidelines aim to standardize the comparison of drug permeability data obtained from laboratory tests (in vitro), animal and human studies (in vivo), and computer simulations (in silico). This convergence of approaches is crucial for the development of more precise and reliable drugs that can effectively treat diseases.

Understanding drug permeability is not merely a scientific curiosity but a critical requirement in drug development. If a drug cannot traverse biological barriers effectively, it will fail to exert its therapeutic action, regardless of theoretical efficacy. Dr. Christian Jorgensen, a researcher from the University of Portsmouth’s School of Medicine, Pharmacy and Biomedical Sciences, emphasizes the importance of this research. He reflects on his years of experience in a U.S. hospital, where he faced significant obstacles in reconciling permeability data from different testing modalities. This experience reinforces the necessity of multidisciplinary collaboration in drug development.

The statistics concerning drug approval rates underscore the issues at hand. Between 2000 and 2015, a mere 14 percent of drugs entering clinical trials were granted FDA approval in the United States. This staggering figure illustrates the need for enhanced permeability testing to ensure that drugs not only reach their targets efficiently but also minimize potential side effects. Improved understanding of these processes could lead to a fundamental shift in how drugs are developed, with life-saving therapies successfully reaching patients who need them.

The published study in the Journal of Chemical Information and Modeling sheds light on the critical importance of understanding drug movement across all biological barriers, notably the notoriously challenging blood-brain barrier. This barrier is particularly relevant for treatments aimed at neurological disorders, thus making the researchers’ focus on complex systems a profound strength of their findings. By establishing comprehensive guidelines, the authors hope to accelerate the pace of drug development, especially for conditions that have long eluded effective therapeutic interventions.

Pharmaceutical researchers typically rely on three primary modalities to assess drug permeability: in silico, in vitro, and in vivo testing. In silico models leverage computer algorithms to predict how drugs interact with biological systems based on their chemical properties. In vitro tests, on the other hand, involve studying drug behavior in controlled laboratory environments using living cells. Finally, in vivo studies provide critical insights by testing the drug within a living organism. Each testing method has its unique advantages, yet their results have historically been challenging to harmonize, resulting in discrepancies that could jeopardize drug development efforts.

To navigate these complexities, the new guidelines emphasize the importance of consistency in experimental practices, the management of data variability, and adherence to the FAIR principles—ensuring data is Findable, Accessible, Interoperable, and Reusable. Recognizing these factors is vital for researchers aspiring to improve the accuracy of permeability assessments and ultimately enhance drug delivery mechanisms. Collaboration across various scientific fields is underscored as a necessary step toward achieving these goals.

Professor Martin Ulmschneider from King’s College London highlights the ambitious objective of providing clear benchmarks and recommendations to refine permeability testing practices. The aim is not only to enhance individual experiments but to create a unified framework that fosters reliable comparison across the scientific community. This collaborative atmosphere could lead to a heightened understanding of therapeutic mechanisms and the identification of potential bottlenecks in the drug development pipeline.

The researchers involved in this study are committed to creating a landscape of enhanced collaboration and shared knowledge. The hope is that through consistent, unified testing protocols, pharmaceutical companies and researchers will be better equipped to garner the evidence needed for drug approvals. A fundamental reevaluation of how permeability testing is conducted across different fields could yield dividends in both the speed and efficacy of drug development, particularly for those targeting complex diseases.

Navigating the complexities presented by biological barriers remains a significant hurdle in the realm of drug development, but the introduction of these new guidelines represents a crucial step forward. The potential for accelerated development of life-saving therapies—especially for challenging conditions like neurological disorders—creates a compelling narrative around this research. Through rigorous adherence to these protocols and collaborative efforts, these researchers endeavor to change the landscape of drug development, ultimately bringing more effective treatments to market.

This pioneering research not only contributes to the scientific literature but also holds significant promise for real-world applications. As the pharmaceutical industry grapples with the dual challenges of complex biological barriers and regulatory scrutiny, these new guidelines present a long-awaited solution. By bridging the gaps in drug permeability testing, they offer a pathway to more effective research and development processes, benefitting both researchers and patients alike in the quest for improved therapeutic outcomes.

The implications of this research extend far beyond theoretical discussions; they pave the way toward tangible advancements in drug delivery systems. By focusing collective efforts on standardization and collaboration, the scientific community can enhance the cradle-to-grave journey of drug development, from initial testing all the way through to clinical application. The lessons learned from this research are poised to reverberate throughout the fields of pharmacology, medicine, and beyond.

Ultimately, this work affirms the importance of harmonizing scientific investigation across different methodologies. The ramifications of improved permeability testing could reshape not only the success rates for drug candidates but also the landscape of therapeutic strategies for diseases that have previously resisted effective treatment. As these guidelines take root, the hope is that a new era of drug development will emerge, marked by greater efficacy, improved patient outcomes, and a sharper focus on the complexities of drug delivery.

Subject of Research: Drug permeability testing and guidelines for drug delivery
Article Title: Permeability Benchmarking: Guidelines for Comparing in Silico, in Vitro, and in Vivo Measurements
News Publication Date: 17-Jan-2025
Web References: University of Portsmouth
References: Journal of Chemical Information and Modeling
Image Credits: Not specified

Keywords: Drug development, permeability testing, therapeutic efficacy, biological barriers, collaboration in science, drug delivery mechanisms.